# REMAP ECMO - Beta Receptor Modulation Trial

> **NCT06522594** · PHASE2 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Heart Failure
- Cardiogenic Shock

## Interventions

- **DRUG:** Esmolol

## Key facts

- **NCT ID:** NCT06522594
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06522594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06522594, "REMAP ECMO - Beta Receptor Modulation Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06522594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*